

CV ai fini della pubblicazione

SAMANTHA CIALFI

Curriculum Vitae

Place Rome

Date 02-08-24

Part I – General Information

Full Name	SAMANTHA CIALFI
Spoken Languages	Italian, English

Part II – Education

Type	Year	Institution	Notes (Degree, Experience,...)
University graduation	2002	Sapienza University - Rome, Italy	Degree in Biological Sciences - Biotechnology field
PhD	2008	Sapienza University - Rome, Italy	PhD in Immunological Sciences 4-year program School of Medicine
Licensure	2003	University of Tuscia - Viterbo, Italy	License in Biologist Profession n. AA_060119
National Scientific Habilitation for Associate Professor	2022	MIUR, the Italian Ministry of Education, Universities and Research	Sector 06/N1 – Sciences of Health Care Professions and Applied Medical Technologies.
National Scientific Habilitation for Associate Professor	2022	MIUR, the Italian Ministry of Education, Universities and Research	Sector 06/A2 - General Pathology and Clinical Pathology.

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
2019	2024	Department of Molecular Medicine - Sapienza University of Rome	Fixed-term researcher, type A- RTD-A
2017	2018	Department of Molecular Medicine - Sapienza University of Rome	Research Fellow category B type 2 funded by Sapienza University of Rome
2015	2016	Department of Biology and Biotechnologies “Charles Darwin” - Sapienza University of Rome	Research Fellow category B type 2 funded by P.O.N.

2012	2015	Department of Molecular Medicine - Sapienza University of Rome	Research Fellow category B type 2 funded by Telethon
2008	2008	Department of Experimental Medicine - Sapienza University of Rome	Professional Biologist funded by European Union
2007	2008	Department of Experimental Medicine - Sapienza University of Rome	Research Fellow funded by Istituto Pasteur - Fondazione Cenci Bolognetti
2003	2003	Department of Experimental Medicine - Sapienza University of Rome	Research Fellow funded by Istituto Pasteur - Fondazione Cenci Bolognetti

IIIB – Other Appointments

Start	End	Institution	Position
2008	2012	Polyclinic Umberto I of Rome	Professional Biologist funded by Io...domani Association

Part IV – Teaching experience

Year	Institution	Lecture/Course
2021-present	Sapienza University of Rome	Professor of General Pathology (SSD/MED04) in the course of Cellular and Molecular Basis of Life - CdL Dental Hygiene B - L/SNT3
2021-present	Sapienza University of Rome	Professor of Pathology e Pathophysiology (SSD/MED04) in the course of Physiopathologic basis of diseases - CdL Nursing P - L/SNT1
2021-2022	Sapienza University of Rome	Professor of General Pathology (SSD/MED04) in the integrated course of Pathology and General Physiopathology - CdL Medicine and Surgery D - LM-41
2022	Sapienza University of Rome	Attività didattica Professionalizzante (ADP) CdL Medicine and Surgery F
2018-2021	Sapienza University of Rome	Lecturer of "Sviluppo e applicazione di tecniche di biochimica e biologia molecolare a scopo diagnostico" - PhD course of Molecular Medicine

Part V - Partecipation in International and National Meetings

VA - International Meetings

Year	
2023	Notch Meeting XII Athens - Greece Oral presentation Title: "Loss of ATP2C1 function promotes trafficking and degradation of Notch1: implication in Hailey-Hailey Disease"
2019	42nd European Cystic Fibrosis Conference (ECFC) Liverpool - United Kingdom Poster Presentation Title: "A pilot study on oxidative stress in cystic fibrosis: the involvement of miR-125b and HO-1"
2019	42nd European Cystic Fibrosis Conference (ECFC) Liverpool - United Kingdom Poster Presentation Title: Cataloguing outcome measures of cystic fibrosis clinical studies"
2013	European Respiratory Society (ERS) Annual Congress Barcelona - Spain Poster Presentation Title: "miR145 and SMAD3 expression in patients with Cystic Fibrosis"
2013	36th European Cystic Fibrosis Conference (ECFC) Lisboa - Portugal Selection Oral Presentation Title: "Overexpression of miR-494 and miR-145 correlates with CFTR and SMAD3 down-regulation in Cystic Fibrosis patients"

VB - National Meetings

Year	
2018	XIV SIFC National Congress, Salerno - Italy Poster Presentation Title: "miR125b/NRF2/CFTR circuitry: a pilot study on oxidative stress in cystic fibrosis "
2012	XVIII SIFC National Congress, Tirrenia - Italy Oral presentation Title: "Elevati livelli del miR-494 e del miR-145 correlano con una diminuita espressione di CFTR e SMAD3 in pazienti con fibrosi cistica"
2011	XVII SIFC National Congress, Tirrenia - Italy Oral presentation Title: "Mir-101 e mir-494 controllano in modo sinergico la regolazione post-trascrizionale del trascritto CFTR mediante legame a siti specifici nella regione 3'UTR".

Part VI - Society memberships, Awards and Honors

Year	Title
2020 - present	Member of REPRISE (Register of Expert Peer Reviewers for Italian Scientific Evaluation)
2012	Best Poster Award. XVIII SIFC National Congress, Tirrenia Italy

Title: Elevati livelli del miR-494 e del miR-145 correlano con una diminuita espressione di CFTR e SMAD3 in pazienti con fibrosi cistica

Part VII - Funding Information [grants as PI-principal investigator or I - investigator]

Year	Title	Program	Grant value
2022 - 2025	PI in the project: "NRF2/miR125b axis: signaling network of oxidative stress and inflammation in cystic fibrosis outcome"	University Sapienza Funding # SP1221847B216911	
2020 - 2023	PI in the project: "Notch/p21/Ask1 axis in skin cancer development"	University Sapienza Funding # RP120172B9502C72	
2021 - 2024	I in the project: "The influence of tumor microenvironment in the progression of Notch-dependent T-cell acute lymphoblastic leukemia: exploring the role of PD-1/PD-L1 axis"	University Sapienza Funding # RM12117A71419448	
2018 - 2021	I in the project: "From thymocyte egression to T-cell Acute Lymphoblastic Leukemia development: identification of new targets for T-ALL therapy"	University Sapienza Funding # PH118164340087CF	
2017 - 2020	I in the project: "Oxidative-stress and Notch link in keratinocyte transformation and differentiation"	University Sapienza Funding # RM11715C7D97EC8D	
2015 - 2016	I in the project: "Nanotecnologie e nanomateriali per i beni culturali"	P.O.N. Miur #PON03PE_00214_1 (CUPB62F14000560005)	
2015 - 2018	I in the project: "Crosstalk between oxidative stress and Notch1: Impact on skin cancer"	AIRC #IG15218	
2012 - 2015	I in the project: "Calcium dysregulation and oxidative stress from molecular mechanism to therapeutic implication in Hailey-Hailey disease"	Telethon #GGP12264	
2011- 2012	I in the project: "Small RNA nel neuroblastoma e nel rabdomiosarcoma in età pediatrica: studio della "signature" tumorale	Associazione Fabrizio Procaccini	

	come nuovo parametro diagnostico e prognostico		
2009-2013	I in the project: "Characterization of CXCR4/SDF-1 and Wnt/beta-catenin signaling in Rhabdomyosarcomas"		
2008 - 2011	I in the project: "Dissection of Notch-dependent pathways involved in development of T cell leukemia: insights from mouse models"	AIRC #IG5432	
2008	I in the project: "Novel approaches to pathogenesis, diagnosis and treatment of autoimmune diseases based on new insights into thymus-dependent self-tolerance"	European Union Eurothymaide # LSHB-CT-2003-503410	
2008	I in the project: "Notch signaling in Development and Pathology"	European Commission FP7 prpgram #NotchIT-PITN-GA-2008-215761	

Part VIII – Research Activities

Keywords	Brief Description
Notch signaling and Cancer	Study of dual role of Notch as oncogene and tumour suppressor gene paying specific attention to modifications driving transformation and neoplastic processes together with its deregulated functions on proliferation and differentiation in different cellular contexts, leukemia and skin cancer especially. [doi: 10.1016/j.yexcr.2005.01.015; doi: 10.1182/blood-2005-07-2823; doi: 10.1038/onc.2009.446; doi: 10.1371/journal.pone.0032047; doi: 10.1038/leu.2012.192; doi: 10.4161/cc.29079; doi: 10.1016/j.bbagr.2014.06.017; doi: 10.1016/j.neo.2014.10.004; doi: 10.1038/leu.2015.117; doi: 10.1074/jbc.RA119.009881; doi: 10.1038/s41420-021-00459-3; doi: 10.3390/ijms23020829; doi: 10.3389/fonc.2022.918763]
Hailey-Hailey Disease pathogenesis	Study of molecular mechanisms underlying Hailey-Hailey Disease (HHD) and signaling pathways that control the epithelial growth and differentiation. Involvement of oxidative stress response deregulation together with impaired Notch signaling in pathophysiology of this rare disease. Screening and evaluation of treatments with specific molecules to find new and effective therapeutic strategies: <i>in vitro</i> on yeast and on human cellular models; <i>in vivo</i> clinical studies of phase II. [doi: 10.1111/j.1365-2133.2009.09500.x; doi: 10.1111/j.1600-0625.2011.01359; doi: 10.1111/ced.12203; doi: 10.1038/srep31567; doi: 10.1016/j.bbamcr.2016.08.002; doi: 10.1038/srep44514; doi: 10.3390/ijms19061814; doi:10.3390/molecules24244427; doi: 10.1111/exd.14769].

Cystic Fibrosis, miRNA and Oxidative stress	Study of miRNAs role in exacerbation and progression of Cystic Fibrosis as an additional level of control over the mutation of the channel CFTR, to understand how genetic background affects clinical variability. Identification of miRNAs as modifier genes directly controlling the expression of chlorine channel and proteins involved in inflammatory response and disease severity, to use them as biomarkers for diagnosis and prognosis. Using patient samples, study of crosstalk between oxidative stress, NRF2 pathway, miRNA and inflammation, affecting exacerbations and progression of this genetic disease to obtain new therapeutic drugs for personalized treatments. [doi:10.1371/journal.pone.0026601; doi:10.1016/j.jcf.2013.03.007; doi:10.3892/etm.2021.10017].
---	--

Part IX – Summary of Scientific Achievements

Total indexed Publications

Product type	Number	Data Base	Start	End
Papers [international]	34	PubMed, ISI Web of Science, Scopus	2005	2024

Total Impact factor	160,835 (WOS)
Average Impact factor per Product	4,73
Total Citations	854 (Scopus)
Average Citations per Product	25,12 (Scopus)
Hirsch (H) index	20 (Scopus)
Normalized H index*	1,11
Number of indexed Publications of last 10 years	20

*H index divided by the academic seniority.

- 1) Talora C, **Cialfi S**, Segatto O, Morrone S, Choi JK, Frati L, Dotto GP, Gulino A and Screpanti I. *Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways*
Exp. Cell Res. 2005; 305: 343 – 354.
IF: 4,148 (WOS) Citations: 72 (Scopus)
- 2) Talora C, **Cialfi S**, Oliviero C, Palermo R, Pascucci M, Frati L, Vacca A, Gulino A and Screpanti I. *Cross talk among Notch3, pre-TCR and Tal1 in T-cell development and leukemogenesis*
Blood 2006; 107 (8): 3313 – 3320.
IF: 10,37 (WOS) Citations: 37 (Scopus)

- 3) Checquolo S, Palermo R, **Cialfi S**, Ferrara G, Oliviero C, Talora C, Bellavia D, Giovenco A, Grazioli P, Frati L, Gulino A, Screpanti I. *Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leucemia*
Oncogene. 2010 Mar 11;29(10):1463-74. Epub 2009 Dec 7.
IF: 7,414 (WOS) Citations: 27 (Scopus)

- 4) Donfrancesco A, De Ioris MA, McDowell HP, De Pasquale MD, Ilari I, Jenkner A, Castellano A, **Cialfi S**, De Laurentis C and Dominici C. *Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response*
Pediatric Blood Cancer 2010; 54(1): 55-6.
IF: 1,948 (WOS) Citations: 18 (Scopus)

- 5) **Cialfi S**, Oliviero C, Ceccarelli S, Marchese C, Barbieri L, Biolcati G, Uccelletti D, Palleschi C, Barboni L, De Bernardo C, Grammatico P, Magrelli A, Salvatore M, Taruscio D, Frati L, Gulino A, Screpanti I and Talora C. *Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease*
Br.J Dermatol. 2010; 162(3):518-526.
IF: 4,353 (WOS) Citations: 36 (Scopus)

- 6) **Cialfi S**, Uccelletti D, Carducci A, Wésolowski-Louvel M, Mancini P, Heipieper HJ, Saliola M. *KIHsl1 is a component of glycerol response pathways in the milk yeast Kluyveromyces lactis*
Microbiology SGM. 2011 May;157(Pt 5):1509-18. Epub 2011 Feb 10.
IF: 3,061 (WOS) Citations: 12 (Scopus)

- 7) Manca S, Magrelli A, **Cialfi S**, Lefort K, Ambra R, Alimandi M, Biolcati G, Uccelletti D, Palleschi C, Screpanti I, Candi E, Melino G, Salvatore M, Taruscio D, Talora C. *Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation.*
Exp Dermatol. 2011 Nov; 20(11):932-7. Epub 2011 Sep 14.
IF: 3,543 (WOS) Citations: 57 (Scopus)

- 8) Megiorni F, **Cialfi S**, Dominici C, Quattrucci S, Pizzuti A. *Synergistic post-transcriptional regulation of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by miR-101 and miR-494 specific binding*
PLoS One 2011;6(10): e26601. Epub 2011 Oct 20.
IF: 4,092 (WOS) Citations: 75 (Scopus)

- 9) Benelli D*, **Cialfi S***, Pinzaglia M, Talora C and Londei P. *The translation factor eIF6 is a Notch-dependent regulator of cell migration and invasion*
PLoS One 2012;7(2): e3204. Epub 2012 Feb 14.
*Equal contribution
IF: 3,73 (WOS) Citations: 24 (Scopus)

- 10) **Cialfi S**, Palermo R, Manca S, Checquolo S, Bellavia D, Pelullo M, Quaranta R, Dominici C, Gulino A, Screpanti I, Talora C. *Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression*
Leukemia 2013 Feb. 27(2):485-844.
IF: 9,379 (WOS) Citations: 30 (Scopus)
- 11) Cattelani S, Ferrari-Amorotti G, Galavotti S, Defferrari R, Tanno B, **Cialfi S**, Vergalli J, Fragiasso V, Guerzoni C, Manzotti G, Soliera AR, Menin C, Bertorelle R, McDowell HP, Inserra A, Belli ML, Varesio L, Tweddle D, Tonini GP, Altavista P, Dominici C, Raschella G, Calabretta B. *The p53 Codon 72 Pro/Pro Genotype Identifies Poor-Prognosis Neuroblastoma Patients: Correlation with Reduced Apoptosis and Enhanced Senescence by the p53-72P Isoform*
Neoplasia. 2012 Jul;14(7):634-43
IF: 5,47 (WOS) Citations: 20 (Scopus)
- 12) Saliola M, Tramonti A, Lanini C, **Cialfi S**, De Biase D and Falcone C. *Intracellular NADPH levels affect the oligomeric state of the glucose 6-phosphate dehydrogenase*
Eukaryotic Cell 2012 Dec;11(12):1503-11.
IF: 3,586 (WOS) Citations: 23 (Scopus)
- 13) Megiorni F*, **Cialfi S***, Cimino G, De Biase RV, Dominici C, Quattrucci S, Pizzuti A. *Elevated levels of miR-145 correlate with SMAD3 down-regulation in Cystic Fibrosis patients.*
J Cyst Fibros. 2013 Dec;12(6):797-802.
*Equal contribution
IF: 3,82 (WOS) Citations: 52 (Scopus)
- 14) Annavarapu S*, **Cialfi S***, Dominici C, Kokai G, Uccini S, Ceccarelli S, McDowell HP, Helliwell T. *Characterization of Wnt/b-catenin signaling in rhabdomyosarcoma*
Lab Invest. 2013 Oct;93(10):1090-9.
*Equal contribution
IF: 3,828 (WOS) Citations: 28 (Scopus)
- 15) Biolcati G, Aurizi C, Barbieri L, **Cialfi S**, Screpanti I, Talora C. *Efficacy of the melanocortin analogue Nle4-D-phe7- α -MSH in the treatment of patients affected by Hailey-Hailey disease.*
Clin Exp Dermatol. 2014 Mar;39(2):168-75.
IF 1,092 (WOS) Citations 33 (Scopus)
- 16) **Cialfi S**, Palermo R, Manca S, De Blasio C, Vargas Romero P, Checquolo S, Bellavia D, Uccelletti D, Saliola M, D'Alessandro A, Zolla L, Gulino A, Screpanti I, Talora C. *Loss of Notch1-dependent p21 (Waf1/Cip1) expression influences the Notch1 outcome in tumorigenesis.*
Cell Cycle. 2014 13(13): 2046-55.

IF 4,565 (WOS) Citations 29 (Scopus)

- 17) Zampieri M, Ciccarone F, Palermo R, **Cialfi S**, Passananti C, Chiaretti S, Nocchia D, Talora C, Screpanti I, Caiafa P. *The epigenetic factor BORIS/CTCF regulates the Notch3 gene expression in cancer cells.*
Biochim Biophys Acta. 2014 Sep; 1839(9): 813-25.
IF 6,332 (WOS) Citations 29 (Scopus)
- 18) Megiorni F*, **Cialfi S***, McDowell HP, Felsani A, Camero S, Guffanti A, Pizer B, Clerico A, De Grazia A, Pizzuti A, Moles A, Dominici C. *Deep sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.*
BMC Cancer 2014 Nov 25; 14:880.
*Equal contribution
IF 3,362 (WOS) Citations 58 (Scopus)
- 19) Pelullo M, Quaranta R, Talora C, Checquolo S, **Cialfi S**, Felli MP, te Kronnie G, Borga C, Besharat ZM, Palermo R, Di Marcotullio L, Capobianco AJ, Gulino A, Screpanti I, Bellavia D. *Notch3/Jagged1 circuitry reinforces notch signaling and sustain T-ALL.*
Neoplasia 2014 Dec; 16(12): 1007-17.
IF 4,252 (WOS) Citations 46 (Scopus)
- 20) Vargas Romero P, **Cialfi S**, Palermo R, De Blasio C, Checquolo S, Bellavia D, Chiaretti S, Foà R, Amadori A, Gulino A, Zardo G, Talora C, Screpanti I. *The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPalpha.*
Leukemia 2015 Dec;29(12):2442-5.
IF 12,104 (WOS) Citations 28 (Scopus)
- 21) Zanni E, De Palma S, Chandraiahgari CR, De Bellis G, **Cialfi S**, Talora C, Palleschi C, Sarto MS, Uccelletti D and Mancini P. *In vitro toxicity studies of zinc oxide nano- and microrods on mammalian cells: a comparative analysis.*
Materials Lett 2016; 179:90-94.
IF 2,572 (WOS) Citations 22 (Scopus)
- 22) **Cialfi S**, La Pera L, De Blasio C, Mariano G, Palermo R, Zonfrilli A, Uccelletti D, Palleschi C, Biolcati G, Barbieri L, Screpanti I, Talora C. *The loss of ATP2C1 impairs the DNA damage response and induces altered skin homeostasis: Consequences for epidermal biology in Hailey-Hailey disease.*
Sci Rep. 2016 Aug 16;6: 31567.
IF 4,259 (WOS) Citations 19 (Scopus)
- 23) Ficociello G, Zanni E, **Cialfi S**, Aurizi C, Biolcati G, Palleschi C, Talora C, Uccelletti D. *Glutathione S-transferase θ - subunit as a phenotypic suppressor of pmr1 Δ strain, the Kluyveromyces lactis model for Hailey-Hailey disease.*
Biochim Biophys Acta. 2016 Nov;1863(11):2650-2657.
IF 4,521 (WOS) Citations 7 (Scopus)
- 24) Megiorni F, Colaiaacovo M, **Cialfi S**, McDowell HP, Guffanti A, Camero S, Felsani A, Losty PD, Pizer B, Shukla R, Cappelli C, Ferrara E, Pizzuti A, Moles A and Dominici C. *A sketch of*

known and novel MYC-associated miRNA network in neuroblastoma.

Oncol Rep 2017; 38(1):3-20.

IF 2,976 (WOS) Citations 21(Scopus)

- 25) Ficociello G, Zonfrilli A, **Cialfi S**, Talora C, Uccelletti D. *Yeast based screen to identify natural compounds with a potential therapeutic effect in Hailey-Hailey disease.*
Int J Mol Sci 2018; 19(6) pii:E1814.
IF 4,183 (WOS) Citations 5 (Scopus)
- 26) Verma N, Franchitto M, Zonfrilli A, **Cialfi S**, Palermo R., Talora C. *DNA damage stress: Cui prodest?*
Int J Mol Sci 2019; 20(5), 1073.
IF 4,556 (WOS) Citations 13 (Scopus)
- 27) De Blasio C.D., Zonfrilli A., Franchitto M., Mariano G, **Cialfi S**, Verma N, Checquolo S, Bellavia D, Palermo R, Benelli D, Screpanti, I., Talora, C. *PLK1 targets NOTCH1 during DNA damage and mitotic progression.*
JBC 2019; 294(47), 17941-17950.
IF 4,238 (WOS) Citations 15 (Scopus)
- 28) **Cialfi S***, Calabro S, Franchitto M, Zonfrilli A, Screpanti, I., Talora, C*. *Hypotonic, acidic oxidizing solution containing hypochlorous acid (HClO) as a potential treatment of Hailey Hailey disease.*
Molecules 2019; 24(24), 4427.
*Corresponding author
IF 3,267 (WOS) Citations 3 (Scopus)
- 29) Micale L, **Cialfi S**, Fusco C, Cinque L, Castellana S, Biagini T, Talora C, Notarangelo A, Bisceglia L, Taruscio D, Salvatore M, Castori M. *Novel TONSL variants cause SPONASTRIME dysplasia and associate with spontaneous chromosome breaks, defective cell proliferation and apoptosis.*
Hum Mol Gen 2020; 29(18), 3122-3131.
IF 6,15 (WOS) Citations 4 (Scopus)
- 30) Pelullo M, Savi D, Quattrucci S, Cimino G, Pizzuti A, Screpanti I, Talora C, **Cialfi S**. *miR-125b/NRF2/HO-1 axis is involved in protection against oxidative stress of cystic fibrosis: A pilot study.*
Exp Ther Med. 2021 Jun;21(6):585.
IF 2,751 (WOS) Citations 7 (WOS)
- 31) De Blasio C, Verma N, Moretti M, **Cialfi S**, Zonfrilli A, Franchitto M, Truglio F, De Smaele E, Ichijo H, Naguro I, Screpanti I, Talora C. *Functional cooperation between ASK1 and p21^{Waf1/Cip1} in the balance of cell-cycle arrest, cell death and tumorigenesis of stressed keratinocytes.*
Cell Death Discov. 2021 Apr 12;7(1):75.
IF 7,113 (WOS) Citations 2 (Scopus)

- 32) Del Gaizo M, Sergio I, Lazzari S, **Cialfi S**, Pelullo M, Screpanti I, Felli MP. *MicroRNAs as Modulators of the Immune Response in T-Cell Acute Lymphoblastic Leukemia*. **Int J Mol Sci**. 2022 Jan 13;23(2):829.
IF 5,6 (WOS) Citations 6 (Scopus)

- 33) Pelullo M, Zema S, De Carolis M, **Cialfi S**, Giuli MV, Palermo R, Capalbo C, Giannini G, Screpanti I, Checquolo S, Bellavia D. *5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance*. **Front Oncol**. 2022 Jul 1;12:918763.
IF 4,7 (WOS) Citations 3 (Scopus)

- 34) Zonfrilli A, Truglio F, Simeone A, Pelullo M, De Turre V, Benelli D, Checquolo S, Bellavia D, Palermo R, Uccelletti D, Screpanti I, **Cialfi S ***, Talora C*. *Loss of ATP2C1 function promotes trafficking and degradation of NOTCH1: implications for Hailey-Hailey disease*. **Exp Dermatol**. 2023 Feb 14.
*Corresponding authors
IF 3,5 (WOS) Citations 0 (Scopus)

Part X– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF *(if applicable), citations**, press/media release (if any).

Notes:

* Journal Impact Factors of the year of publication are indicated.

** Scopus was used to calculate citations.

Bold first author and/or last or corresponding author.

Number of first/last/corresponding author publications: 6

- 1) Biolcati G, Aurizi C, Barbieri L, **Cialfi S**, Screpanti I, Talora C. *Efficacy of the melanocortin analogue Nle4-D-phe7- α -MSH in the treatment of patients affected by Hailey-Hailey disease*. **Clin Exp Dermatol**. 2014 Mar;39(2):168-75.
IF 1,092 (WOS) Citations 33 (Scopus)

- 2) **Cialfi S**, Palermo R, Manca S, De Blasio C, Vargas Romero P, Checquolo S, Bellavia D, Uccelletti D, Saliola M, D'Alessandro A, Zolla L, Gulino A, Screpanti I, Talora C. *Loss of Notch1-dependent p21 (Waf1/Cip1) expression influences the Notch1 outcome in tumorigenesis*. **Cell Cycle** 2014 13(13): 2046-55.
IF 4,565 (WOS) Citations 29 (Scopus)

- 3) Megiorni F*, **Cialfi S***, McDowell HP, Felsani A, Camero S, Guffanti A, Pizer B, Clerico A, De Grazia A, Pizzuti A, Moles A, Dominici C. *Deep sequencing the microRNA profile in*

rhabdomyosarcoma reveals down-regulation of miR-378 family members.

BMC Cancer 2014 Nov 25; 14:880.

*Equal contribution

IF 3,362 (WOS) Citations 58 (Scopus)

- 4) Vargas Romero P, **Cialfi S**, Palermo R, De Blasio C, Checquolo S, Bellavia D, Chiaretti S, Foà R, Amadori A, Gulino A, Zardo G, Talora C, Screpanti I. *The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPalpha.* Leukemia 2015 Dec;29(12):2442-5
IF 12,104 (WOS) Citations 28 (Scopus)
- 5) **Cialfi S**, La Pera L, De Blasio C, Mariano G, Palermo R, Zonfrilli A, Uccelletti D, Palleschi C, Biolcati G, Barbieri L, Screpanti I, Talora C. *The loss of ATP2C1 impairs the DNA damage response and induces altered skin homeostasis: Consequences for epidermal biology in Hailey-Hailey disease.* Sci Rep. 2016 Aug 16;6: 31567.
IF 4,259 (WOS) Citations 19 (Scopus)
- 6) Ficociello G, Zanni E, **Cialfi S**, Aurizi C, Biolcati G, Palleschi C, Talora C, Uccelletti D. *Glutathione S-transferase θ - subunit as a phenotypic suppressor of pmr1 Δ strain, the Kluyveromyces lactis model for Hailey-Hailey disease.* Biochim Biophys Acta. 2016 Nov;1863(11):2650-2657.
IF 4,521 (WOS) Citations 7 (Scopus)
- 7) De Blasio C.D., Zonfrilli A., Franchitto M., Mariano G, **Cialfi S**, Verma N, Checquolo S, Bellavia D, Palermo R, Benelli D, Screpanti, I., Talora, C. *PLK1 targets NOTCH1 during DNA damage and mitotic progression.* JBC, 2019; 294(47), 17941-17950.
IF 4,238 (WOS) Citations 15 (Scopus)
- 8) Ficociello G, Zonfrilli A, **Cialfi S**, Talora C, Uccelletti D. *Yeast based screen to identify natural compounds with a potential therapeutic effect in Hailey-Hailey disease.* Int J Mol Sci 2018; 19(6) pii:E1814.
IF 4,183 (WOS) Citations 5 (Scopus)
- 9) **Cialfi S***, Calabro S, Franchitto M, Zonfrilli A, Screpanti, I., Talora, C*. *Hypotonic, acidic oxidizing solution containing hypochlorous acid (HClO) a a potential treatment of Hailey-Hailey disease.* Molecules 2019; 24(24), 4427.
*Corresponding authors.
IF 3,267 (WOS) Citations 3 (Scopus)
- 10) Pelullo M, Savi D, Quattrucci S, Cimino G, Pizzuti A, Screpanti I, Talora C, **Cialfi S**. *miR-125b/NRF2/HO-1 axis is involved in protection against oxidative stress of cystic fibrosis: A pilot study.* Exp Ther Med. 2021 Jun;21(6):585.
IF 2,751 (WOS) Citations 7 (WOS)

- 11) De Blasio C, Verma N, Moretti M, **Cialfi S**, Zonfrilli A, Franchitto M, Truglio F, De Smaele E, Ichijo H, Naguro I, Screpanti I, Talora C. *Functional cooperation between ASK1 and p21^{Waf1/Cip1} in the balance of cell-cycle arrest, cell death and tumorigenesis of stressed keratinocytes.*
Cell Death Discov. 2021 Apr 12;7(1):75.
IF 7,113 (WOS) Citations 2 (Scopus).
- 12) Zonfrilli A, Truglio F, Simeone A, Pelullo M, De Turre V, Benelli, Checquolo S, Bellavia D, Palermo R, Uccelletti D, Screpanti I, **Cialfi S** *, Talora I*. *Loss of ATP2C1 function promotes trafficking and degradation of NOTCH1: implications for Hailey-Hailey disease.*
Exp Dermatol. 2023 Jun;32(6): 787-798
*Corresponding authors.
IF 3,5 (WOS) Citations 0 (Scopus)

Part XI– Meeting Acta published on International Journal indexed on ISI Web of Science

- 1) **Cialfi S**, McDowell HP, Altavista P, Boldrini R, Bosco S, Clerico A, Jenkner A, Kokai G, Pizer B, Dominici C. ABC drug transporter gene expression in neuroblastoma.
J Clin Onc 2010. 28(15) Supp S, 9524. doi: 10.1200/jco.2010.28.15_suppl.9524.
IF: 18,97 Citations: 4
- 2) Dominici C, **Cialfi S**, McDowell HP, Altavista P, Boldrini R, Bosco S, Castellano A, Clerico A, Cozzi DA, Inserra A, Jenkner A, Kokai G, Losty PD, Pizer B, Dominici C. ABC drug transporter gene expression in neuroblastoma.
Ped Blood Cancer 2010 55(5): 892. doi.org/10.1002/pbc.22779.
IF: 1,948 Citations 0
- 3) Rao AS, **Cialfi S**, Dominici C, Yao S, Foster CS, Kokai G, Helliwell TR, McDowell HP. Characterisation of Wnt signaling pathway in rhabdomyosarcoma.
J Path 2011 224 Supp 2: S16. doi.org/10.1002/path.2957.
IF: 6,318 Citations 0

Firma

(non soggetta ad autentica ai sensi dell'art.39 del D.P.R. 28.12.2000, n.445)